Next Article in Journal
Results from the Adverse Event Sedation Reporting Tool: A Global Anthology of 7952 Records Derived from >160,000 Procedural Sedation Encounters
Next Article in Special Issue
Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents
Previous Article in Journal
Correlation between Hepatitis B Virus Infection and Colorectal Neoplasia
Previous Article in Special Issue
History of Inflammatory Bowel Diseases
Open AccessArticle

Preventive Effect of Cardiotrophin-1 Administration before DSS-Induced Ulcerative Colitis in Mice

1
Department of Gastroenterology, University Hospital of Salamanca, 37007 Salamanca, Spain
2
Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain.
3
Bio-inRen S.L. Faculty of Medicine, Campus Miguel de Unamuno, 37007 Salamanca, Spain
4
Department of Human Anatomy and Histology, University of Salamanca, 37007 Salamanca, Spain
5
Department of Physiology and Pharmacology, University of Salamanca, 37007 Salamanca, Spain
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work and share first authorship.
J. Clin. Med. 2019, 8(12), 2086; https://doi.org/10.3390/jcm8122086
Received: 10 October 2019 / Revised: 19 November 2019 / Accepted: 22 November 2019 / Published: 1 December 2019
(This article belongs to the Special Issue Ulcerative Colitis: Current and Emerging Treatment Strategies)
Ulcerative colitis is a relatively frequent, chronic disease that impacts significantly the patient’s quality of life. Although many therapeutic options are available, additional approaches are needed because many patients either do not respond to current therapies or show significant side effects. Cardiotrophin-1 (CT-1) is a cytokine with potent cytoprotective, anti-inflammatory, and antiapoptotic properties. The purpose of this study was to assess if the administration of CT-1 could reduce colon damage in mice with experimental colitis was induced with 5% dextran sulfate sodium (DSS) in the drinking water. Half of the mice received an i.v. dose of CT-1 (200 µg/kg) 2 h before and 2 and 4 days after DSS administration. Animals were followed during 7 days after DSS administration. The severity of colitis was measured by standard scores. Colon damage was assessed by histology and immunohistochemistry. Inflammatory mediators were measured by Western blot and PCR. CT-1 administration to DSS-treated mice ameliorated both the clinical course (disease activity index), histological damage, inflammation (colon expression of TNF-α, IL-17, IL-10, INF IFN-γ, and iNOS), and apoptosis. Our results suggest that CT-1 administration before induction of colitis improves the clinical course, tissue damage, and inflammation in DSS-induced colitis in mice. View Full-Text
Keywords: apoptosis; cardiotrophin-1; colon; inflammation apoptosis; cardiotrophin-1; colon; inflammation
Show Figures

Figure 1

MDPI and ACS Style

Sánchez-Garrido, A.I.; Prieto-Vicente, V.; Blanco-Gozalo, V.; Arévalo, M.; Quiros, Y.; López-Montañés, D.; López-Hernández, F.J.; Rodríguez-Pérez, A.; López-Novoa, J.M. Preventive Effect of Cardiotrophin-1 Administration before DSS-Induced Ulcerative Colitis in Mice. J. Clin. Med. 2019, 8, 2086.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop